Eli Lilly plans to sell two versions of its Humalog insulin at half the list price starting in mid-April, the drugmaker said Jan. 14.
It will create two generic versions of its Humalog Kwikpens that will be listed at prices 50 percent lower than its branded version.
Eli Lilly previously created the lispro injection, which was a generic, half-priced version of Humalog, in May 2019, but as of August, a GoodRx analysis found that lispro was not widely used.
A survey released in December by Sens. Elizabeth Warren, D-Mass., and Richard Blumenthal, D-Conn., claimed that lispro did not lower costs for diabetes patients.
Eli Lilly said that about 10 percent of people using Humalog have transitioned to lispro.
With the two new versions, Eli Lilly said most Humalog users will have an option to reduce their out-of-pocket costs.
Both of the new versions will have list prices of $265.20 for a package of five Kwikpens.
Read the full news release here.